StocksCellectis SACLLS

CLLS

Cellectis SA

18.85 0.75 (4.14%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
18.85
B
18.96

Cellectis SA

Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. It is a clinical-stage biopharmaceutical company, focused on developing and marketing genetically-edited T-cell- based immuno-oncology products for treating leukemia patients. The company also develops innovative plant-based products... Show More
Last Month
10,274
Followers
0.59%
Investors
100% Of them have BUY positions.
An Increase of 0.50% from last trading Day

Related Markets

Turtle Beach Corp
HEAR
2.92 (11.82%)
S
27.60
B
27.65
Fomento de Construcciones
FCC.MC
-0.09 (-0.83%)
S
10.71
B
10.77
Editas Medicine Inc
EDIT
1.43 (4.16%)
S
35.77
B
35.90
Bouygues SA
EN.PA
-0.33 (-0.95%)
S
34.24
B
34.32
Summit Materials Inc
SUM
0.90 (3.19%)
S
29.05
B
29.16
View More
Pinned Post
eToroInvestment
☀️ 𝗗𝗮𝗶𝗹𝘆 𝗩𝗼𝗹𝘂𝗺𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗨𝗽𝗱𝗮𝘁𝗲 ☀️ 🚀Top 10 instruments with the highest surge in trading volumes yesterday🚀 Here are the Top 10 instruments available to trade on eToro which experienced the highest surge in trading volumes yesterday compared to their average daily volume over... Show More
Like CommentShare
null
.
Market Feed
Top
DrazykInvest
$EDIT (Editas Medicine Inc) Goldman Sachs analyst Madhu Kumar initiated coverage of Editas Medicine with a sell rating today and a price target of 20$. This of course caused the stock to drop significantly. It is the weakest CRISPR stock at the moment with the weakest pipeline and least advanced results.... Show More